CAJ | 학술논문

目的探讨莫沙必利联合奥美拉唑治疗胃食管反流病的临床疗效和安全性。方法2010年1月～2012年12月我院收治的128例胃食管反流病患者，进行随机分组，其中64例作为研究组（M组），M组患者给予枸橼酸莫沙必利联合奥美拉唑治疗，对照组64例（D组）患者仅单纯给予奥美拉唑治疗，两组疗程均为8周，比较分析两组患者的临床疗效与不良反应。结果观察组患者治疗总有效率达到92.27％，观察组患者治疗总有效率达到8O.48％，两组患者在治疗有效率比较上差异具有统计学意义( P<0.05)，内镜疗效上观察组患者的总有效率显著高于对照组患者的总有效率，差异具有统计学意义( P<0.05)，两组患者在不良反应构成比较差异无统计学意义( P>0.05)，两组患者在不良反应分布上具有差异，观察组患者不良反应主要为腹泻、便秘和口干，对照组患者不良反应主要表现为便秘、恶心呕吐、头晕头痛。结论枸橼酸莫沙必利联合奥美拉唑用于胃食管反流病的临床疗效优于单独使用奥美拉唑的治疗效果，且不良反应少，安全性高，值得临床推广应用。
목적탐토막사필리연합오미랍서치료위식관반류병적림상료효화안전성。방법2010년1월～2012년12월아원수치적128례위식관반류병환자，진행수궤분조，기중64례작위연구조（M조），M조환자급여구연산막사필리연합오미랍서치료，대조조64례（D조）환자부단순급여오미랍서치료，량조료정균위8주，비교분석량조환자적림상료효여불량반응。결과관찰조환자치료총유효솔체도92.27％，관찰조환자치료총유효솔체도8O.48％，량조환자재치료유효솔비교상차이구유통계학의의( P<0.05)，내경료효상관찰조환자적총유효솔현저고우대조조환자적총유효솔，차이구유통계학의의( P<0.05)，량조환자재불량반응구성비교차이무통계학의의( P>0.05)，량조환자재불량반응분포상구유차이，관찰조환자불량반응주요위복사、편비화구간，대조조환자불량반응주요표현위편비、악심구토、두훈두통。결론구연산막사필리연합오미랍서용우위식관반류병적림상료효우우단독사용오미랍서적치료효과，차불량반응소，안전성고，치득림상추엄응용。
Objective: To study the efficacy and safety of convention drug treatment of parkinson’s disease (PD) while adding pramipexole clinica1.Methods:January 2010 to December 2012 in our hospital 186 cases of Parkinson's patients were in Hoehn-Yahr stage I ~I I level, the patient voluntarily joined the study, were randomized, of which 90 cases as the study group (P group), patients on the basis of the original levodopa plus pramipexole (Boehringer Ingelheim, Germany) treatment, a starting dose of pramipexole was 0.25 mg /d, gradual y increase the amount based on the clinical symptoms and safety of pramipexole daily dose was increased to 4.5 mg (1.5 mg, 3 times / d), the clinical symptoms improved and stable dose of the drug as a maintenance dose12 weeks for a course. 96 cases in the control group (Group D) patients continue to simply taking L-dopa treatment. Results:Before treatment UPDRS scores compared the difference was not statistical y different (P> 0.05), UPDRS scores were significantly decreased after treatment of the P group of patients, the difference was statistical y significant (P <0.05), D group of patients after treatment UPDRS scores before treatment, the difference was not statistical y significant (P> 0.05). After 12 weeks of treatment, the study group, 72 cases (80.00%) markedly effective in 45 cases, the control group (46.88%), the difference was statistical y significant (P <0.05). In the course of treatment, the two groups of patients were not serious adverse reactions (P> 0.05). Conclusion:The application of L-dopa treatment of Parkinson’s patients on the basis of adding pramipexole treatment Can effectively al eviate the symptoms of the disease,improve patient quality of life, Should be widely applied.